Cargando…
Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model
Although the pathogenesis of atopic dermatitis (AD) remains to be fully deciphered, skin barrier abnormality and immune dysregulation are known to be involved. Recently, the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) system has also been implicated in the pathogenesis of this mu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658216/ https://www.ncbi.nlm.nih.gov/pubmed/36362286 http://dx.doi.org/10.3390/ijms232113498 |
_version_ | 1784829895893843968 |
---|---|
author | Sung, Bokyung Baek, Yi-Yong Kim, Young-Myeong You, Ji Chang |
author_facet | Sung, Bokyung Baek, Yi-Yong Kim, Young-Myeong You, Ji Chang |
author_sort | Sung, Bokyung |
collection | PubMed |
description | Although the pathogenesis of atopic dermatitis (AD) remains to be fully deciphered, skin barrier abnormality and immune dysregulation are known to be involved. Recently, the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) system has also been implicated in the pathogenesis of this multifactorial chronic inflammatory skin disorder. Previously, we showed that a novel tetrapeptide, N-acetyl-Arg-Leu-Tyr-Glu (Ac-RLYE), inhibits angiogenesis and vascular permeability effectively by selectively antagonizing VEGFR-2. The current study aimed to investigate the pharmacological effect of Ac-RLYE on AD in vitro and in vivo. The in vitro experiments demonstrated that Ac-RLYE inhibited VEGF-induced vascular permeability in endothelial cells. Moreover, in an in vivo animal model of AD, Ac-RLYE relieved AD-like symptoms such as ear thickness and dermatitis severity scores and infiltration of immune cells, including mast cells and eosinophils. Ac-RLYE inhibited IgE secretion, restored the skin barrier protein filaggrin level, and markedly downregulated gene expression of AD-related Th1, Th2, and Th17 cytokines. Collectively, these findings suggest that Ac-RLYE would be useful for the treatment of AD and associated inflammatory skin disorders. |
format | Online Article Text |
id | pubmed-9658216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96582162022-11-15 Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model Sung, Bokyung Baek, Yi-Yong Kim, Young-Myeong You, Ji Chang Int J Mol Sci Article Although the pathogenesis of atopic dermatitis (AD) remains to be fully deciphered, skin barrier abnormality and immune dysregulation are known to be involved. Recently, the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) system has also been implicated in the pathogenesis of this multifactorial chronic inflammatory skin disorder. Previously, we showed that a novel tetrapeptide, N-acetyl-Arg-Leu-Tyr-Glu (Ac-RLYE), inhibits angiogenesis and vascular permeability effectively by selectively antagonizing VEGFR-2. The current study aimed to investigate the pharmacological effect of Ac-RLYE on AD in vitro and in vivo. The in vitro experiments demonstrated that Ac-RLYE inhibited VEGF-induced vascular permeability in endothelial cells. Moreover, in an in vivo animal model of AD, Ac-RLYE relieved AD-like symptoms such as ear thickness and dermatitis severity scores and infiltration of immune cells, including mast cells and eosinophils. Ac-RLYE inhibited IgE secretion, restored the skin barrier protein filaggrin level, and markedly downregulated gene expression of AD-related Th1, Th2, and Th17 cytokines. Collectively, these findings suggest that Ac-RLYE would be useful for the treatment of AD and associated inflammatory skin disorders. MDPI 2022-11-04 /pmc/articles/PMC9658216/ /pubmed/36362286 http://dx.doi.org/10.3390/ijms232113498 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sung, Bokyung Baek, Yi-Yong Kim, Young-Myeong You, Ji Chang Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model |
title | Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model |
title_full | Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model |
title_fullStr | Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model |
title_full_unstemmed | Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model |
title_short | Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model |
title_sort | topical administration of a novel acetylated tetrapeptide suppresses vascular permeability and immune responses and alleviates atopic dermatitis in a murine model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658216/ https://www.ncbi.nlm.nih.gov/pubmed/36362286 http://dx.doi.org/10.3390/ijms232113498 |
work_keys_str_mv | AT sungbokyung topicaladministrationofanovelacetylatedtetrapeptidesuppressesvascularpermeabilityandimmuneresponsesandalleviatesatopicdermatitisinamurinemodel AT baekyiyong topicaladministrationofanovelacetylatedtetrapeptidesuppressesvascularpermeabilityandimmuneresponsesandalleviatesatopicdermatitisinamurinemodel AT kimyoungmyeong topicaladministrationofanovelacetylatedtetrapeptidesuppressesvascularpermeabilityandimmuneresponsesandalleviatesatopicdermatitisinamurinemodel AT youjichang topicaladministrationofanovelacetylatedtetrapeptidesuppressesvascularpermeabilityandimmuneresponsesandalleviatesatopicdermatitisinamurinemodel |